FindTrial
Sign In

SHR3680

DRUG9 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Fudan University

Conditions

Breast CancerCastration-resistant Prostate CancerDrug-drug Interaction,SHR3680Healthy ParticipantsHepatic ImpairmentHormone Refractory Prostate CancerHormone-Dependent Prostate CancerMetastatic Cancer

Phase 1

A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients
NCT02691975
Jiangsu HengRui Medicine Co., Ltd.Hormone Refractory Prostate Cancer, Metastatic Prostate Carcinoma
Start: 2016-04-12End: 2021-06-01Updated: 2020-05-13
A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
TerminatedNCT03741712
Jiangsu HengRui Medicine Co., Ltd.Castration-resistant Prostate Cancer, Prostate Cancer
Start: 2018-11-20End: 2020-12-08Updated: 2021-02-05
Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride
NCT04621669
Jiangsu HengRui Medicine Co., Ltd.Drug-drug Interaction,SHR3680
Start: 2020-11-19End: 2021-07-05Target: 18Updated: 2020-11-09
An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants
NCT04631549
Jiangsu HengRui Medicine Co., Ltd.Healthy Participants, Hepatic Impairment
Start: 2021-02-03End: 2023-07-31Target: 24Updated: 2022-12-01

Phase 2

A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
TerminatedNCT04102124
Jiangsu HengRui Medicine Co., Ltd.Castration-resistant Prostate Cancer, Prostate Cancer
Start: 2019-04-08End: 2021-08-31Updated: 2025-06-24
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
NCT04355858
Fudan UniversityBreast Cancer, Metastatic Cancer
Start: 2020-05-01End: 2025-04-01Target: 319Updated: 2022-07-26
A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC
NCT04603833
Jiangsu HengRui Medicine Co., Ltd.Prostate Cancer Metastatic
Start: 2020-12-02End: 2022-12-31Target: 150Updated: 2021-02-21

Phase 3

A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer
NCT03520478
Jiangsu HengRui Medicine Co., Ltd.Hormone-Dependent Prostate Cancer, Prostate Cancer
Start: 2018-05-30End: 2025-04-30Updated: 2021-03-02
A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
TerminatedNCT05009290
Jiangsu HengRui Medicine Co., Ltd.Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Start: 2021-11-01End: 2024-09-06Updated: 2026-04-03

Related Papers

Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study
Signal Transduction and Targeted Therapy2024-12-172 citations
Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial.
2024-10-163 citations
Rezvilutamide (REZ) plus docetaxel (DOC) in patients (pts) with chemo-naïve metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone (ABI).
Journal of Clinical Oncology2024-06-01
Patient-reported outcomes (PROs) for rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC): An analysis of the CHART randomized, open-label, phase 3 trial.
Journal of Clinical Oncology2024-06-01
Abstract PO1-15-07: Subtyping-directed precision treatment refines traditional one-size-fits-all therapy in HR+/HER2- breast cancer: a sub-study of the MULAN umbrella trial
Cancer Research2024-05-02
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.
2022-09-0549 citations
A phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).
Journal of Clinical Oncology2022-06-014 citations
Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial.
2022-03-0417 citations
SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study.
Journal of Clinical Oncology2020-02-193 citations